About

Provided by Gibbons P.C.

Gibbons brings to bear experience and skill in various practice areas to address the many unique issues faced by the biotechnology and pharmaceutical industries, with attorneys in the intellectual property, litigation, corporate, tax, and antitrust areas available to handle the full range of legal issues companies in these industries face.

We are engaged in the defense of manufacturers of ethical pharmaceutical and medical/surgical devices and diagnostic laboratories, as a focus area within its comprehensive general litigation practice. The firm has defended a number of major pharmaceutical companies, medical device manufacturers, and laboratories in complex actions related to adverse effects, warning, manufacture, and use of products, devices, and implants, as well as the results of laboratory analyses.

Gibbons provides for the complete protection of compounds, technologies, formulas, designs, programs, and intellectual endeavors of all kinds. The patent prosecution and licensing of rapidly developing technologies and innovative products are all within our scope, and we have been involved in every type of intellectual property litigation, including representation of clients in the defense and prosecution of their pharmaceutical and biopharmaceutical patent and license rights, breach of confidentiality agreements, and various infringements on copyrighted materials. We are also highly experienced in trademark and copyright registration and protection of trade secrets.

Chambers Review

Provided by Chambers
Life Sciences - New Jersey
1
Band 1
What the team is known for

Gibbons has a highly respected litigation team which is well known for its representations of life sciences clients. The Newark-based group is particularly noted for its strength in handling a range of cases concerning products liability, patent infringement and Hatch-Waxman disputes.

Notable practitioners

Kim Catullo and David De Lorenzi are key contacts.

Work Highlights

Provided by Gibbons P.C.
  • Gibbons defended Bristol-Myers Squibb, Celgene and Celgene in patent litigation, alleging that that the defendants' ZEPOSIA drug product infringed the plaintiffs' patents.